Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Daewoong-Pharma

More Like This

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

PR Newswire associated0

Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market

PR Newswire associated0

Daewoong Therapeutics Gets MFDS Nod for Phase 1 IND for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema

Delta-Fly Pharma Inc.: Notice of Initiation of Phase III Pivotal comparative clinical trial of DFP-14323

Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

Alentis Receives FDA Orphan Drug Designation for Lixudebart to Treat Idiopathic Pulmonary Fibrosis

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera